NCT02070471

Phase 2 Study to Evaluate the Efficacy, Safety and PK of Intravenous Single Injection LC28-0126 Immediately Before PCI in STEMI Patients

A Multicenter, Randomized, Parallel Group, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Intravenous Single Injection LC28-0126 Immediately Before PCI (Percutaneous Coronary Intervention) in Patients With STEMI(ST-segment Elevation Myocardial Infarction)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: LG Life Sciences · Industry
• Sex: All
• Age: 20 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Evaluate the efficacy, Safety and Pharmacokinetics of Intravenous single injection LC28-0126 immediately before PCI (Percutaneous Coronary Intervention) in Patients with STEMI (ST-segment Elevation Myocardial Infarction)

Conditions

• ST-segment Elevation Myocardial Infarction

Interventions

Type	Name	Description
DRUG	Placebo	Placebo
DRUG	LC28-0126 Dose A	LC28-0126 Dose A
DRUG	LC28-0126 Dose B	LC28-0126 Dose B
DRUG	LC28-0126 Dose C	LC28-0126 Dose C

Timeline

• Start date: 2014-01-01
• Primary completion: 2015-06-01
• First posted: 2014-02-25
• Last updated: 2016-05-10

Locations

1 site across 1 country: South Korea